Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in…
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co.,…
Read More...
Read More...
Browsing Tag
Hepatocellular
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in…
<!-- Name:DistributionId Value:8827692 -->
<!--…
Read More...
Read More...
Hepatocellular Carcinoma Drugs Market is Forecasted to Reach Nearly USD 1.95 Billion by 2030, Size,…
SYDNEY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Hepatocellular Carcinoma Drugs…
Read More...
Read More...
The Role of TKIs in Hepatocellular Carcinoma
MedPage Today brought together three…
Read More...
Read More...
Combination Treatment Approaches in Hepatocellular Carcinoma
MedPage Today brought together three…
Read More...
Read More...
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma
MedPage Today brought together three…
Read More...
Read More...
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter…
WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company…
Read More...
Read More...
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the…
EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage…
Read More...
Read More...
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for…
CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrateThe unique degradation…
Read More...
Read More...
HCC Recurrence More Common in Men After Curative Surgery
After curative hepatectomy…
Read More...
Read More...